BB BIOTECH AG
- WKN: A0NFN3
- ISIN: CH0038389992
- Land: Switzerland
Nachricht vom 24.05.2022 | 07:30
BB BIOTECH AG: Disruptive technologies are changing an entire industry
DGAP-News: BB BIOTECH AG
/ Key word(s): Market Report
Market commentary, 24 May 2022
Dr. Daniel Koller, Head Investment Team BB Biotech at Bellevue Asset Management
Disruptive technologies are changing an entire industry
The biotech industry is increasingly applying next-generation therapeutic approaches to develop drugs for diseases and conditions with larger populations of patients. The sales potential of these therapeutics is large as well.
From the standpoint of both drug developers and the investment community, the successful development of COVID-19 vaccines and treatments clearly dominated the biotech industry’s innovative power and achievements during the past two years. This “wow” effect is now receding. At the same time, financial markets are shifting their attention to chronic and severe diseases with high prevalence rates. Important advances in biomedical technology that have so far been used to develop treatments for orphan diseases are now being applied more frequently in clinical trials to treat diseases affecting large numbers of people.
The biotech industry will benefit from this because it has pioneered a range of new therapeutic approaches. A large number of biotech companies that had previously been focused on rare diseases have begun to widen the scope of their R&D projects to include diseases with larger patient numbers. Next-generation technologies with huge disruptive potential are being applied here. More and more product candidates not only address indications with high unmet medical needs that have so far been difficult to treat, they also hold out the promise of a complete cure. Several of our portfolio companies will present groundbreaking clinical study results this year.
Moderna’s new vaccines soon ready
This year's headline events for Moderna, a core position in BB Biotech’s portfolio, will likely be the trial readouts for its Omicron-specific booster vaccine and mRNA-1010 flu vaccine. Its next-generation mRNA vaccines are expected to be superior to conventional flu vaccines in terms of efficacy and efficiency because they include other antigens and virus strains besides the typical four vaccine virus components selected annually by the WHO. If efforts to launch a combination vaccine against influenza and coronavirus are successful, the world market for flu vaccines, which currently has an annual volume of about 500 million doses, would grow significantly, and perhaps even double in size. Combination vaccines could appeal to people who are skeptical of repeated single-dose vaccinations. The relatively short development timelines and good tolerability profiles of mRNA vaccines would make today's leaders in this field – Moderna, Biontech and Pfizer – the big winners of such a breakthrough. Industry experts estimate that the price of combination vaccines could be set at up to USD 60 per dose, which gives an indication of the tremendous sales potential.
Applying mRNA technology to develop flu treatments is only one steppingstone in Moderna's long-term road map. Moderna is currently pursuing three key Phase III trials. In addition to its flu vaccine program, it is working on a vaccine for RSV, a virus that can cause severe respiratory infections in infants and young children, and a vaccine for cytomegalovirus (CMV). Currently, there are no treatment options for this herpes virus, which can cause hearing loss and other defects or developmental disabilities in babies.
Genome editing – blockbuster technology
Genome editing, a technology that promises to permanently cure genetic diseases, is on the verge of a major commercial breakthrough. This technology is used to cut out, repair or replace defective fragments of human DNA identified as genetic triggers of disease. Crispr Therapeutics has partnered with Vertex Pharma in developing treatments for beta thalassemia and sickle cell disease. Current treatments for these genetic disorders of red blood cells, which cause serious, even life-threatening complications, are inadequate.
Due to a specific genetic predisposition, the severe form of sickle cell anemia is dominant in the United States, affecting some 50 000 people. Beta thalassemia, also referred to as Mediterranean anemia, is more prevalent in southern Europe, whereas the number of people in the United States who have the severe form of this disease is about 1000. Genome editing is designed to provide a permanent cure following a single treatment. Regulatory approval of the first therapy based on this technology would revolutionize the treatment of this disease. A company offering such a one-time gene-therapy treatment would have considerable pricing power. Crispr and Vertex Pharma will be the first to announce top-line data from a pivotal trial and to submit a marketing authorization application. If their product does enter the market in 2023 as expected, it is forecast to generate annual peak sales in the billions.
Using artificial intelligence to build new platforms
Rational drug design is a novel approach that uses artificial intelligence (AI) and machine learning to analyze the molecular motions of protein molecules and better understand disease processes. Portfolio company Relay Therapeutics has three cancer drugs in clinical Phase I studies targeting pathogenic proteins that were previously not viable target molecules for therapeutic purposes. Black Diamond Therapeutics, another company in BB Biotech’s portfolio, uses machine-learning tools to develop novel precision oncology therapies that are designed to work across a number of tumor types.
For further information:
|Company:||BB BIOTECH AG|
|Phone:||+41 52 624 08 45|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Mailand, SIX|
|EQS News ID:||1359163|
|End of News||DGAP News Service|
BB Biotech AG publishes its interim report
BB BIOTECH AG: First signs of increased M&A ac ...
BB BIOTECH AG: Disruptive technologies are cha ...
BB Biotech AG publishes its interim report
BB BIOTECH AG: Increased investment level bala ...
GBC im Fokus
ISA gAG: Attraktive Wandelanleihe
Die International School Augsburg begibt Wandelanleihe als weiteren Finanzierungsbaustein des geplanten Schulneubaus; unserer Einschätzung nach liegen attraktive Konditionen vor und die Anleihe ist von der ISA gAG solide finanzierbar; das Wertpapier ist aus unserer Sicht sowohl für das Unternehmen als auch für die Investoren ein attraktives Investment.
Events im Fokus
12./13. Oktober 2022: Fachkonferenz Finanzdienstleistungen/Technologie
Der AKTIONÄR News
06. August 07:45 Allianz: Reaktionen auf die schwachen Zahlen
06. August 09:03 Die Reiselust kehrt zurück – und Alphabet scheffelt Milliarden
06. August 11:30 LVMH: Citigroup sieht weitere 25 Prozent Aufwärtspotenzial
News im Fokus
Allianz SE: Allianz erzielt ein operatives Ergebnis von 3,5 Milliarden Euro im zweiten Quartal - Konzern bestätigt Ausblick für das Gesamtjahr
05. August 2022, 06:59
Conference Call 15.08.2022 (Webcast)
15. August 2022
Original-Research: GK Software SE (von Montega AG): Kaufen
05. August 2022